Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

ClinicalTrials.gov ID: NCT04890613

Public ClinicalTrials.gov record NCT04890613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation

Study identification

NCT ID: NCT04890613
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Senhwa Biosciences, Inc.; Industry
Enrollment: 52 participants

Conditions and interventions

Conditions

Advanced Solid Tumor

Interventions

CX-5461 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 7, 2021
Primary completion: Feb 28, 2027
Completion: Feb 28, 2027
Last update posted: Apr 27, 2026

2021 – 2027

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
University of California, Los Angeles	Santa Monica	California	90404	Recruiting
H. Lee Moffitt Cancer Center and Research Institute Hospital	Tampa	Florida	33612-9497	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Memorial Sloan-Kettering Cancer Center	New York	New York	10065	Withdrawn
Ohio State University-James Cancer Hospital and Solove Research Institute	Columbus	Ohio	43202	Recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04890613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 27, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04890613 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →